Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-07-27

Clinical Trial Results: A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A multicenter Phase 1/2 study evaluating recombinant vaccinia virus therapy for malignant melanoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Recombinant Vaccinia Virus

Snippet

Sponsor: Jennerex Biotherapeutics | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-07-27